3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 3
1
Status
Recruiting
3
Active not recruiting
1
Sponsor Class
INDUSTRY
4
OTHER
3
Study Type
Interventional
4
Sponsor
Cancer Type
Genitourinary
4
Thoracic
2
Head & Neck
2
Gynecologic
2
Gastrointestinal
2
Breast
2
Conditions
Carcinoma, Non-Small-Cell Lung
249
Breast Neoplasms
136
Neoplasms
130
Colorectal Neoplasms
114
Prostatic Neoplasms
95
Neoplasm Metastasis
89
Multiple Myeloma
89
Ovarian Neoplasms
84
Lung Neoplasms
83
Recurrence
64
Squamous Cell Carcinoma of Head and Neck
61
Pancreatic Neoplasms
57
Endometrial Neoplasms
54
Melanoma
48
Leukemia, Lymphocytic, Chronic, B-Cell
46
Small Cell Lung Carcinoma
45
Stomach Neoplasms
44
Leukemia, Myeloid, Acute
44
Carcinoma, Renal Cell
44
Lymphoma, Non-Hodgkin
40
Advanced Solid Tumors
39
Lymphoma, Large B-Cell, Diffuse
38
Parkinson Disease 4, Autosomal Dominant Lewy Body
36
Urinary Bladder Neoplasms
34
Head and Neck Neoplasms
34
Triple Negative Breast Neoplasms
33
Lymphoma, Follicular
32
Carcinoma, Hepatocellular
31
Esophageal Neoplasms
27
Myasthenia Gravis
26
Interventions
pembrolizumab
2
enfortumab vedotin
2
Radiation Dose Hypofractionation
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
INDUSTRY
×
Urologic Neoplasms
×
30 days
×
Clear all
NCT06238479
2026-05-22
EXCEED
Eli Lilly and Company
Phase 1
Active not recruiting
490 enrolled
NCT06465069
2026-05-22
NEXUS-01
Eli Lilly and Company
Phase 1
Recruiting
420 enrolled
NCT05614739
2026-05-19
FORAGER-1
Eli Lilly and Company
Phase 1
Recruiting
535 enrolled
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled